Revelstoke Capital Partners Recapitalizes AOM Infusion
April 15, 2025
Revelstoke Capital Partners completed a recapitalization of AOM Infusion, a specialty infusion provider that delivers IVIG, biologics and other therapies for chronic conditions. Revelstoke will support AOM's management team to expand therapeutic focus areas, deepen clinical expertise and grow the company's patient reach; terms were not disclosed.
- Buyers
- Revelstoke Capital Partners
- Targets
- AOM Infusion
- Industry
- Healthcare Services
- Location
- Texas, United States
- Transaction Type
- Recapitalization
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.